View:
[ADMA LETTERHEAD]
May 23, 2012
VIA EDGAR
|
Mr. Justin Dobbie
Legal Branch Chief
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
|
|
Re:
|
ADMA Biologics, Inc.
Amendment No. 2 to Form 8-K
Filed April 24, 2012
File No. 000-52120
|
Dear Mr. Dobbie:
By letter dated May 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). The Company currently expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing, on or before June 4, 2012.
If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at our outside counsel, SNR Denton US LLP, at (973) 912-7100.
Sincerely,
/s/ Adam S. Grossman
Adam S. Grossman
President and Chief Executive Officer